💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Athersys expands collaboration with Healios; shares ahead 16% premarket

Published 06/07/2018, 07:25 AM
© Reuters.  Athersys expands collaboration with Healios; shares ahead 16% premarket
ATHXQ
-
  • Athersys (NASDAQ:ATHX) has entered into an agreement with HEALIOS K.K. to expand their collaboration into additional therapeutic areas.
  • Healios receives rights to develop and commercialize additional indications and Athersys receives $20M in license fees, milestones payments of up to ~$360M as well as tiered double-digit royalties on MultiStem therapies developed for ARDS, and single-digit royalties for other licensed products.
  • Under the terms of the agreement, Healios will also receive a credit of $10M and a right of first negotiation to broaden the field and territory related to MultiStem cells used in combination with iPSC-derived cells. It has been granted a right of first negotiation regarding an exclusive option for a license to develop and commercialize MultiStem therapy for certain indications in China, and the potential inclusion of an additional indication to the Japan license.
  • Shares of ATHX are up 16% premarket on modest volume.
  • Previously: Healios and Athersys expand MultiStem partnership (March 13)
  • Now read: Athersys/Healios Warrant Structure Bullish For Athersys Shares


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.